Cart
sales@molnova.com
Roniciclib
CAS No. 1223498-69-8
Roniciclib( BAY 10-00394 | BAY1000394 )
Catalog No. M10856 CAS No. 1223498-69-8
A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 121 | In Stock |
|
| 10MG | 177 | In Stock |
|
| 25MG | 296 | In Stock |
|
| 50MG | 454 | In Stock |
|
| 100MG | 787 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRoniciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.
-
DescriptionA novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM; inhibits 16 additional kinase in a panel of 214 non-CDK Ser/Thr and Tyr kinases; simultaneously inhibits cell-cycle progression and RNA polymerase II-mediated gene transcription, shows broad and uniform inhibitory activity on cell proliferation with IC50 of 8-33 nM, potently inhibits growth of various human tumor xenografts.Lung Cancer Phase 2 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsBAY 10-00394 | BAY1000394
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1223498-69-8
-
Formula Weight430.44
-
Molecular FormulaC18H21F3N4O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 250 mg/mL (580.80 mM)
-
SMILESC[C@@H](O)[C@H](OC1=NC(NC2=CC=C(S(=N)(C3CC3)=O)C=C2)=NC=C1C(F)(F)F)C
-
Chemical Name(R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Siemeister G, et al. Mol Cancer Ther. 2012 Oct;11(10):2265-73.
2. Lücking U, et al. ChemMedChem. 2013 Jul;8(7):1067-85.
3. Ayaz P, et al. ACS Chem Biol. 2016 Jun 17;11(6):1710-9.
4. Bahleda R, et al. Br J Cancer. 2017 Jun 6;116(12):1505-1512.
molnova catalog
related products
-
TAK-931
TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
-
CDK-IN-10
CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.
-
G1T38
G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
